What it is
Dihexa is a small-molecule research compound, not a conventional peptide, studied in preclinical neurobiology.
Mechanism and research questions
- Research has examined binding to hepatocyte growth factor and effects on synaptogenic signaling.
- The proposed mechanism remains preclinical and should not be presented as a cognitive treatment.
Human evidence
No robust human clinical evidence was identified in the initial audit.
Preclinical / mechanistic evidence
Animal and cellular work has examined synaptic and cognitive endpoints.
Evidence summary
The directly located literature is preclinical; no robust human efficacy or safety program was identified.
Limits and interpretation
- Not a peptide; classify it as a small molecule.
- Preclinical cognitive findings do not establish human benefit.
- No dosing or human-use guidance is provided.
Regulatory and identity note
Research small molecule; not presented as an approved medicine.